- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
- February 2015
Mathematicians are developing a blood flow model for metastasis.
- January 2015
René Bernards on discovering effective drug combinations.
- December 2014
Research on the high rate of burnout among young oncologists.
- November 2014
Carl June on the efficacy of CAR-T cells in treating leukaemia.
- October 2014
News from ESMO 2014 with Solange Peters and Alexander Eggermont.
- September 2014
Discussing how healthcare systems can meet the needs of cancer survivors.
EJC News Focus – May 2013
Highlights of 2nd ESTRO Forum
By the year 2020, it is estimated that for every tumour, data will be available on 10,000 markers related to survival. How are clinicians to make sense – and practical use – of it all?
According to ESTRO President, Vincenzo Valentini, a good way to start might be to involve radiation oncologists who already have expertise in complex imaging and dose-planning models. The decision models of the future will become even more sophisticated, he says, able to codify quality of life so that the needs of individual patients can be met.
This was just one of the themes of the 2nd ESTRO Forum (Geneva; 19-23 April 2013). Others included the combination of radiation therapy and drugs; and the use of a single shot of radiotherapy to control pain. Here Vincenzo Valentini discusses the highlights of the forum with Helen Saul.